Sodium-glucose cotransporter 2 (SGLT2) inhibitors, as potential (off-label) anti-obesity agents and effects on cardiovascular risk: A systematic review and meta-analysis
{{output}}
Objectives: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are primarily used for the treatment of type 2 diabetes; however, they have also been reported to be effective in weight loss. We conducted a meta-analysis to consolid... ...
